Skip to main content
Clinical Trials/NCT00784186
NCT00784186
Completed
Not Applicable

Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14 - 21 Weeks LMP): A Randomized-controlled Double-blinded Trial

Gynuity Health Projects2 sites in 1 country120 target enrollmentAugust 2008

Overview

Phase
Not Applicable
Intervention
mifepristone+misoprostol
Conditions
Abortion, Induced
Sponsor
Gynuity Health Projects
Enrollment
120
Locations
2
Primary Endpoint
Rate of successful abortion: defined as complete evacuation using study drug without recourse to any additional intervention.
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

The primary goal of this study is to determine the clinical advantage of pre-treatment with mifepristone in second trimester misoprostol induction abortion. This will be a randomized controlled double-blinded trial of 260 women comparing misoprostol alone to mifepristone plus misoprostol for second trimester (14-21 weeks' LMP) medical abortion.

Registry
clinicaltrials.gov
Start Date
August 2008
End Date
August 2009
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Gynuity Health Projects
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • 14 to 21 weeks gestation, based on menstrual history and clinical exam (with or without ultrasound)
  • Meet legal criteria to obtain abortion
  • Present with closed cervical os and no vaginal bleeding
  • Live fetus at time of presentation for service
  • Have no contraindications to study procedures, according to provider
  • Be able to consent to procedure, either by reading consent document or by having consent document read to her
  • Be willing to follow study procedures

Exclusion Criteria

  • Known previous transmural uterine incision
  • Known allergy to mifepristone or misoprostol/prostaglandin or other contraindications to the use of mifepristone or misoprostol
  • Any contraindications to vaginal delivery, including placenta previa
  • Presentation in active labor (defined as moderate to severe contractions every 10 minutes or less)

Arms & Interventions

mifepristone+misoprostol

200 mg mifepristone followed by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.

Intervention: mifepristone+misoprostol

mifepristone+misoprostol

200 mg mifepristone followed by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.

Intervention: misoprostol

misoprostol

800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.

Intervention: misoprostol

misoprostol

800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.

Intervention: placebo

Outcomes

Primary Outcomes

Rate of successful abortion: defined as complete evacuation using study drug without recourse to any additional intervention.

Time Frame: 24 hours

Secondary Outcomes

  • Rate of fetal expulsion: defined as fetal expulsion with study drug alone.(24 hours)
  • Induction-to-abortion interval(Time elapsed between administration of the first misoprostol dose until expulsion of the fetus.)
  • Total dose of misoprostol.(Assessed at time of complete abortion with study drug alone or when total maximum dose given.)
  • Pain experienced by the woman as self-reported.(Assessed during exit interview.)

Study Sites (2)

Loading locations...

Similar Trials